Clinical Trial

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Protocol Amendment History 4 changes
notable Trial sites expanded: 18 -> 21 locations 2026-06-04
notable Trial sites expanded: 13 -> 16 locations 2026-04-16
notable Primary completion moved earlier: 2029-03-15 -> 2028-11-01 2026-03-31
minor Completion moved earlier: 2029-03-15 -> 2028-11-01 2026-03-31
Trial Details
NCT Number NCT07226349
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor
Enrollment 105 participants
Start Date 2025-12-11
Primary Completion 2028-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-10